BioIntegral Valves
BioIntegral Surgical manufactures cardiac and vascular implants made from all-biological materials, using the No-React® treatment. No-React® is a proprietary detoxification of glutaraldehyde-treated tissue.

BioIntegral Surgical manufactures and sells products for mitral, aortic, and pulmonic valve replacement and repair, as well as repair patches.
The total products set covers mitral valve repair (beyond commodity rings), minimally-invasive valve replacement, a full pediatric product line, all-biological mitral and aortic valves including totally biologic aortic valved conduits, and a full size range of pericardial patches.
BIOCONDUIT™ – the first and only all-biological valved aortic conduit
• Reinfection rates as low as homografts
• No long-term anticoagulation needed in any population
• Available in a variety of sizes to prevent mismatch
• Resists tissue “remodeling” that can lead to dilatation in the Ross procedure
• Zero porosity: one layer of bovine pericardium
• Excellent hemodynamics and easy to implant
• Can be oversized to maximize flow
BIOMITRAL™ I BIOAORTIC™ – All-Biological stented porcine mitral valves
• First replacement valves which avoid use of fabric materials
• Do not require special techniques or instruments
• 15 years of clinical use without any report of stent fracture or tissue failure
• Reinfection rates similar to that of homografts
• Lowest endocarditis reinfection rate of any off-the-shelf solution
• Tested positive for endothelial coverage
BIOPULMONIC™ CONDUIT
INJECTABLE BIOPULMONIC™ - All-Biologic off-pump injectable porcine pulmonic valve
VERSAFLEX™ – Ultra flexible, stented porcine aortic valve
• Designed for ultimate versatility
• Wide clinical application equal to stented valves, while it delivers hemodynamics of a stentless valve
• Doesn’t require special techniques or instruments
• Pledgeted commissures distribute stress of valve closure
• Flexible stent delivers good hemodynamics, but avoids distortion common to stentless valves
• Oversizing possible with full benefits
• Clinically associated with significant increase of EOA and reduction in left ventricular mass
• Over 15 years of clinical use and follow-up, no reports of stent fracture or tissue failure
•Clinically used and proven to avoid reinfection in cases of infective endocarditis